Seaport Therapeutics, Inc. (SPTX)

Seaport Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	46.04	309.1
Short-Term Investments	169.94	-
Cash & Short-Term Investments	215.98	309.1
Cash Growth	-30.13%	-
Other Receivables	3.03	-
Receivables	3.03	-
Prepaid Expenses	1.18	0.39
Other Current Assets	3.04	0.66
Total Current Assets	223.23	310.15
Property, Plant & Equipment	5.23	5.17
Long-Term Investments	17.67	-
Long-Term Deferred Charges	1.2	-
Other Long-Term Assets	1.68	0.45
Total Assets	249.01	315.78
Accounts Payable	2.01	4.73
Accrued Expenses	9.13	5.21
Current Portion of Leases	1.64	0.86
Other Current Liabilities	0.01	0.35
Total Current Liabilities	12.78	11.15
Long-Term Leases	3.44	4.15
Total Liabilities	16.23	15.3
Common Stock	0	0
Additional Paid-In Capital	21.26	14.38
Retained Earnings	-114.11	-39.23
Comprehensive Income & Other	0.3	-
Total Common Equity	-92.55	-24.85
Shareholders' Equity	232.78	300.48
Total Liabilities & Equity	249.01	315.78
Total Debt	5.08	5.01
Net Cash (Debt)	210.9	304.09
Net Cash Growth	-30.65%	-
Net Cash Per Share	28.29	102.68
Filing Date Shares Outstanding	8.15	8.15
Total Common Shares Outstanding	8.15	8.15
Working Capital	210.45	299
Book Value Per Share	-11.35	-3.05
Tangible Book Value	-92.55	-24.85
Tangible Book Value Per Share	-11.35	-3.05
Machinery	0.97	0.98
Leasehold Improvements	0.43	0.1

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q